Last updated on June 2020

A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients


Brief description of study

This study will explore 2 different doses of inotuzumab ozogamicin including the dose that is approved and a lower dose. The main purpose of this study is to evaluate whether a dose of inotuzumab ozogamicin, lower than the approved dose, could be recommended for adult patient with relapsed or refractory ALL who may be at higher risk for severe liver problems after inotuzumab ozogamicin treatment and stem cell transplant (a potentially curative therapy that can replace cancer cells with healthy cells). Efficacy and safety of the 2 doses will be evaluated.

Clinical Study Identifier: NCT03677596

Find a site near you

Start Over

Raffles Hospital

Singapore, Singapore
  Connect »

Raffles Radiology

Singapore, Singapore
  Connect »

Keck Hospital of USC

Los Angeles, CA United States
  Connect »

LAC+USC Medical Center

Los Angeles, CA United States
  Connect »

Alfred Health

Melbourne, Australia
  Connect »

Wake Forest Baptist Health

Winston-Salem, NC United States
  Connect »

CHU Liege

Liege, Belgium
  Connect »